Latest news

• MSD taps Austria’s Themis to bolster vaccine pipeline

  Themis said in a statement however that the alliance is focused on “a vaccine that has the potential to provide a significant benefit to a great number of patients worldwide.”. ... The vaccine delivers the antigens directly to macrophages and

• AZ says Brilinta hits the mark in diabetic heart disease

  The results of the 19, 000-patient THEMIS trial will now form the basis of a regulatory filing later this year to expand the label for Brilinta (ticagrelor) for this ... We look forward to presenting the full results from the THEMIS trial later this year.

• Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

  The product is being developed by Vienna-based vaccines specialist Themis, which has been working on this its lead product since it was founded in 2011. ... Themis’ vaccine candidate has shown a good safety and immune-response data in clinical testing

• Another failed trial knocks back AZ's plan to grow Brilinta

  EUCLID's failure leaves AZ banking on the results of one final cardiovascular outcomes trial - the THEMIS study in patients with type 2 diabetes at high risk of cardiovascular events - to

• AZ's Brilinta disappoints in stroke trial

  The company is still waiting on the results of two other studies - the EUCLID trial in peripheral arterial disease (PAD) and THEMIS in patients with type 2 diabetes at high risk ... EUCLID should generate results later this year while THEMIS is due to